NCT07683754
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07683754
Title T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)
Acronym DB-Guide
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Daiichi Sankyo
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.